2123 related articles for article (PubMed ID: 29405201)
1. Targeting the IL-6/JAK/STAT3 signalling axis in cancer.
Johnson DE; O'Keefe RA; Grandis JR
Nat Rev Clin Oncol; 2018 Apr; 15(4):234-248. PubMed ID: 29405201
[TBL] [Abstract][Full Text] [Related]
2. The IL-6/JAK/STAT3 pathway: potential therapeutic strategies in treating colorectal cancer (Review).
Wang SW; Sun YM
Int J Oncol; 2014 Apr; 44(4):1032-40. PubMed ID: 24430672
[TBL] [Abstract][Full Text] [Related]
3. Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.
Bharadwaj U; Kasembeli MM; Robinson P; Tweardy DJ
Pharmacol Rev; 2020 Apr; 72(2):486-526. PubMed ID: 32198236
[TBL] [Abstract][Full Text] [Related]
4. The tyrosine phosphatase SHP2 increases robustness and information transfer within IL-6-induced JAK/STAT signalling.
Fiebelkow J; Guendel A; Guendel B; Mehwald N; Jetka T; Komorowski M; Waldherr S; Schaper F; Dittrich A
Cell Commun Signal; 2021 Sep; 19(1):94. PubMed ID: 34530865
[TBL] [Abstract][Full Text] [Related]
5. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia.
Bonetto A; Aydogdu T; Jin X; Zhang Z; Zhan R; Puzis L; Koniaris LG; Zimmers TA
Am J Physiol Endocrinol Metab; 2012 Aug; 303(3):E410-21. PubMed ID: 22669242
[TBL] [Abstract][Full Text] [Related]
6. Targeting JAK kinase in solid tumors: emerging opportunities and challenges.
Buchert M; Burns CJ; Ernst M
Oncogene; 2016 Feb; 35(8):939-51. PubMed ID: 25982279
[TBL] [Abstract][Full Text] [Related]
7. The JAK/STAT3 axis: A comprehensive drug target for solid malignancies.
Huynh J; Etemadi N; Hollande F; Ernst M; Buchert M
Semin Cancer Biol; 2017 Aug; 45():13-22. PubMed ID: 28647610
[TBL] [Abstract][Full Text] [Related]
8. Zelnorm, an agonist of 5-Hydroxytryptamine 4-receptor, acts as a potential antitumor drug by targeting JAK/STAT3 signaling.
Zhang L; Song Q; Zhang X; Li L; Xu X; Xu X; Li X; Wang Z; Lin Y; Li X; Li M; Su F; Wang X; Qiu P; Guan H; Tang Y; Xu W; Yang J; Zhao C
Invest New Drugs; 2020 Apr; 38(2):311-320. PubMed ID: 31087223
[TBL] [Abstract][Full Text] [Related]
9. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
[TBL] [Abstract][Full Text] [Related]
10. Revisiting STAT3 signalling in cancer: new and unexpected biological functions.
Yu H; Lee H; Herrmann A; Buettner R; Jove R
Nat Rev Cancer; 2014 Nov; 14(11):736-46. PubMed ID: 25342631
[TBL] [Abstract][Full Text] [Related]
11. Brevilin A, a novel natural product, inhibits janus kinase activity and blocks STAT3 signaling in cancer cells.
Chen X; Du Y; Nan J; Zhang X; Qin X; Wang Y; Hou J; Wang Q; Yang J
PLoS One; 2013; 8(5):e63697. PubMed ID: 23704931
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels.
Xu L; Chen X; Shen M; Yang DR; Fang L; Weng G; Tsai Y; Keng PC; Chen Y; Lee SO
Mol Oncol; 2018 Mar; 12(3):269-286. PubMed ID: 28865178
[TBL] [Abstract][Full Text] [Related]
13. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
Lai SY; Johnson FM
Drug Resist Updat; 2010 Jun; 13(3):67-78. PubMed ID: 20471303
[TBL] [Abstract][Full Text] [Related]
14. IL-6 mediates the signal pathway of JAK-STAT3-VEGF-C promoting growth, invasion and lymphangiogenesis in gastric cancer.
Zhao G; Zhu G; Huang Y; Zheng W; Hua J; Yang S; Zhuang J; Ye J
Oncol Rep; 2016 Mar; 35(3):1787-95. PubMed ID: 26750536
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of microRNA-9 leads to activation of IL-6/Jak/STAT3 pathway through directly targeting IL-6 in HeLa cell.
Zhang J; Jia J; Zhao L; Li X; Xie Q; Chen X; Wang J; Lu F
Mol Carcinog; 2016 May; 55(5):732-42. PubMed ID: 25809226
[TBL] [Abstract][Full Text] [Related]
16. STAT3/5 Inhibitors Suppress Proliferation in Bladder Cancer and Enhance Oncolytic Adenovirus Therapy.
Hindupur SV; Schmid SC; Koch JA; Youssef A; Baur EM; Wang D; Horn T; Slotta-Huspenina J; Gschwend JE; Holm PS; Nawroth R
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32046095
[TBL] [Abstract][Full Text] [Related]
17. Silencing of
Zhang P; Li Z; Yang G
Int J Mol Med; 2021 Dec; 48(6):. PubMed ID: 34713300
[TBL] [Abstract][Full Text] [Related]
18. The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer.
Zhang N; Zeng Y; Du W; Zhu J; Shen D; Liu Z; Huang JA
Int J Oncol; 2016 Oct; 49(4):1360-8. PubMed ID: 27499357
[TBL] [Abstract][Full Text] [Related]
19. SP2509, an inhibitor of LSD1, exerts potential antitumor effects by targeting the JAK/STAT3 signaling.
Zhen H; Zhang X; Zhang L; Zhou M; Lu L; Wu L; He N; Wang J; Li R; Guo Y
Acta Biochim Biophys Sin (Shanghai); 2021 Jul; 53(8):1098-1105. PubMed ID: 34169322
[TBL] [Abstract][Full Text] [Related]
20. Genetic variants in IL-6/JAK/STAT3 pathway and the risk of CRC.
Wang S; Zhang W
Tumour Biol; 2016 May; 37(5):6561-9. PubMed ID: 26638167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
